Table 6.
Intake of Bryophyllum 50% chewable tablets, changes in the doses of anxiolytics/antidepressants during the study, and possible hospital stay after the study.
| Characteristic (Number of Patient Answers After Two and Three Weeks) | Number of Patients or Mean ± SD After Two Weeks | Number of Patients or Mean ± SD After Three Weeks |
|---|---|---|
| Tablet intake (n.a., n = 50) | n.a. | 118 a ± 16 |
| Daily dose of Bryophyllum 50% (n = 47, n = 41) | 5.9 | 5.9 |
| Bryophyllum 50% prescription requested (n.a., n = 54) | n.a. | 32 |
| Dosage of BP changed (n = 48, n = 43) | ||
| Dosage not changed | 41 | 37 |
| Intake stopped | 2 | 1 |
| Dosage reduced | 1 | 2 |
| Intake forgotten | 4 | 3 |
| Dose increase in anxiolytics/antidepressants during the study (n = 42) | 1 b | 2 c (4 products) |
| Dose decrease in medications during the study (n = 37) | 7 d | 1 e |
| Hospital admission after study end (n = 54) | n.a. | 38 |
a Eight patients reported taking more than 132 tablets (corresponding to 6 tablets for 22 days) or returned an empty flask. In those cases, the number of tablets taken was replaced by 132. However, if the patients returned an empty flask but reported some remaining tablets in the flask, the value reported by the patient was used to calculate the chewable tablet intake during the study. b One patient increased their dose of cannabidiol during the first two weeks of the study. c Doses of bromazepam (n = 1), zolpidem (n = 1), escitalopram (n = 1), mirtazapine (n = 1) were reported to be increased during the third week of the study. d The doses of the following medications (including herbal), most with anxiolytic/antidepressant effects, were reported to be decreased during the first two weeks of the study: a product with dry extract of valerian radix and dry extract of hops (n = 1), St John’s Wort (n = 1), mirtazapine (n = 1), cannabidiol (n = 1), a product with valerian, purple passionflower, lemon balm, and butterbur (n = 1), quetiapine (n = 1), and a product with gold and hyoscyamus (n = 1). e The dose of lisdexamfetamine (n = 1) was reported to be decreased during the third week of the study. n.a., not applicable.